Posted inBiotechnology
Allogene’s off-the-shelf CAR-T erases lingering lymphoma cells in early slice of data
Allogene Therapeutics’ gamble on a never-before-seen trial strategy seems to be paying off, with the biotech’s off-the-shelf cell therapy eradicating…









